Market Cap (In USD)
2.34 Billion
Revenue (In USD)
-
Net Income (In USD)
-54.42 Million
Avg. Volume
711.1 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 5.52-60.03
- PE
- -
- EPS
- -
- Beta Value
- 1.091
- ISIN
- US54300N1037
- CUSIP
- 54300N103
- CIK
- 1832168
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Kevin R. Lind
- Employee Count
- -
- Website
- https://www.longboardpharma.com
- Ipo Date
- 2021-03-12
- Details
- Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
More Stocks
-
6095MedPeer,Inc.
6095
-
000540
-
PXPPPhoenix Apps Inc.
PXPP
-
WHITFWhitehaven Coal Limited
WHITF
-
TIPS
-
NODCNodechain, Inc.
NODC
-
SRX
-
SBRANDSSanghvi Brands Limited
SBRANDS